Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is facing short-term weakness due to sensationalized headlines regarding an adverse event reported to the FDA's unadjudicated FAERS database, but this is not related to their key product Foundayo. With an impressive projected EPS of $44.75 in 2027, based on a 27.5x multiple, Eli Lilly shows strong potential for long-term growth and has a BUY rating. Potential risks include slowing growth for key products, negative clinical data, emerging competitors, and broader sector headwinds.

Bears say

Eli Lilly is facing several fundamental risks that are likely to negatively impact its stock performance, including potential pricing and rebate pressures, weak sales trajectory for tirzepatide, disappointing launches of forglipron and pipeline products, and recent acquisitions that may not generate expected returns. These risks are reflected in the company's lower-than-expected 1Q26 EPS estimate of $6.73 compared to the consensus of $6.92, which includes a $0.52 impact from a disclosed IPR&D charge. These factors suggest a negative outlook for the company's stock.

Eli Lilly (LLY) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 19 analysts, Eli Lilly (LLY) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,225.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,225.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.